The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly and Company (NYSE: LLY ... under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...